Suppr超能文献

印度基于丁丙诺啡的阿片类药物替代疗法:一些观察、思考与见解。

Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.

作者信息

Ghosh Abhishek, Basu Debasish, Avasthi Ajit

机构信息

Department of Psychiatry, Drug De-Addiction and Treatment Centre, PGIMER, Chandigarh, India.

Department of Psychiatry, PGIMER, Chandigarh, India.

出版信息

Indian J Psychiatry. 2018 Jul-Sep;60(3):361-366. doi: 10.4103/psychiatry.IndianJPsychiatry_218_17.

Abstract

The most evidence-based treatment for opioid dependence is opioid agonist maintenance treatment also known as opioid substitution therapy (OST). However, there are some critical, yet unaddressed issues of buprenorphine-based substitution therapy, especially in the Indian context. These comprise of generalizability of the evidence for OST, especially for natural and pharmaceutical opioids and for all age groups, optimum dose and duration of OST, and mode of treatment delivery including the frequency of dispensing. Notwithstanding the use of buprenorphine-naloxone combination, abuse and diversion are serious but often underreported problems. There is an urgent need for health services research in India on OST, focusing on these aspects. Rather than directly copying from Western models, it is important to try to understand the useful and safe program and policy options likely to be applicable in the Indian setting, with our own assets as well as vulnerabilities.

摘要

治疗阿片类药物依赖最具循证依据的方法是阿片类激动剂维持治疗,也称为阿片类替代疗法(OST)。然而,基于丁丙诺啡的替代疗法存在一些关键但尚未解决的问题,尤其是在印度的背景下。这些问题包括OST证据的可推广性,特别是对于天然和药用阿片类药物以及所有年龄组而言;OST的最佳剂量和持续时间;以及治疗提供方式,包括配药频率。尽管使用了丁丙诺啡 - 纳洛酮组合,但滥用和转移仍是严重问题,却常常报告不足。印度迫切需要开展关于OST的卫生服务研究,重点关注这些方面。重要的是,不要直接照搬西方模式,而是要结合我们自身的优势和弱点,努力了解可能适用于印度环境的有用且安全的项目和政策选择。

相似文献

1
Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.
Indian J Psychiatry. 2018 Jul-Sep;60(3):361-366. doi: 10.4103/psychiatry.IndianJPsychiatry_218_17.
2
The journey of opioid substitution therapy in India: Achievements and challenges.
Indian J Psychiatry. 2017 Jan-Mar;59(1):39-45. doi: 10.4103/psychiatry.IndianJPsychiatry_37_17.
3
Research on opioid substitution therapy in India: A brief, narrative review.
Indian J Psychiatry. 2018 Jul-Sep;60(3):265-270. doi: 10.4103/psychiatry.IndianJPsychiatry_385_18.
4
The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405.
8
Opioid substitution therapy with buprenorphine-naloxone during COVID-19 outbreak in India: Sharing our experience and interim standard operating procedure.
Indian J Psychiatry. 2020 May-Jun;62(3):322-326. doi: 10.4103/psychiatry.IndianJPsychiatry_295_20. Epub 2020 May 15.
9
Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
J Psychoactive Drugs. 2014 Nov-Dec;46(5):427-35. doi: 10.1080/02791072.2014.960109.
10
The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Drug Alcohol Depend. 2014 Mar 1;136:21-7. doi: 10.1016/j.drugalcdep.2013.12.005. Epub 2014 Jan 8.

引用本文的文献

1
Outcome of Buprenorphine maintenance treatment among Indian females with opioid dependence: Report from a tertiary addiction treatment center.
Indian J Psychiatry. 2025 Mar;67(3):303-309. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_928_24. Epub 2025 Mar 14.
3
Changing Pattern of Opioid Users Attending an Opioid Agonist Treatment Clinic in North India.
J Neurosci Rural Pract. 2022 Feb 9;13(2):176-180. doi: 10.1055/s-0041-1736509. eCollection 2022 Apr.
4
Predictors of retention in the treatment for opioid dependence: A prospective, observational study from India.
Indian J Psychiatry. 2021 Jul-Aug;63(4):355-365. doi: 10.4103/psychiatry.IndianJPsychiatry_448_20. Epub 2021 Aug 7.
5
COVID-19 Pandemic and People Who Use Opioids in India: Opportunities and Evolutions.
Indian J Psychol Med. 2020 Nov 5;42(6):566-568. doi: 10.1177/0253717620965882. eCollection 2020 Nov.
6
Drug misuse in India: Where do we stand & where to go from here?
Indian J Med Res. 2019 Jun;149(6):689-692. doi: 10.4103/ijmr.IJMR_548_19.

本文引用的文献

3
The journey of opioid substitution therapy in India: Achievements and challenges.
Indian J Psychiatry. 2017 Jan-Mar;59(1):39-45. doi: 10.4103/psychiatry.IndianJPsychiatry_37_17.
4
Challenges in the scale-up of opioid substitution treatment in India.
Indian J Psychiatry. 2017 Jan-Mar;59(1):6-9. doi: 10.4103/psychiatry.IndianJPsychiatry_14_17.
6
Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy.
Addiction. 2017 Mar;112(3):415-429. doi: 10.1111/add.13628. Epub 2016 Dec 13.
7
Opioid agonist treatment for pharmaceutical opioid dependent people.
Cochrane Database Syst Rev. 2016 May 9(5):CD011117. doi: 10.1002/14651858.CD011117.pub2.
8
Buprenorphine Prescribing: To Expand or Not to Expand.
J Psychiatr Pract. 2016 May;22(3):183-92. doi: 10.1097/PRA.0000000000000154.
9
Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'?
Subst Abuse Treat Prev Policy. 2016 Mar 8;11:12. doi: 10.1186/s13011-016-0055-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验